Related Experiment Video
Updated: Aug 30, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Pharmacogenetics and public policy: expert views in Europe and North America
David Melzer1, Don Detmer, Ron Zimmern
1Department of Public Health and Primary Care, University of Cambridge, University Forvie Site, Robinson Way, Cambridge CB2 2SR, UK. dm214@ medschl.cam.ac.uk
Abstract:
The new genetics is stimulating the development of genetic testing of patients to help choose the best drug, adjust doses and avoid side effects. Proponents say that this personalized medicine will revolutionize drug development and healthcare. In a series of group meetings, 48 leading experts from regulatory agencies, industry, academia and consumer interests gave their opinions on the public policy priorities. Most believed that pharmacogenetics would have a clear impact on care within 15 years and that a public policy response was needed. The establishment of a good clinical evidence base should be a priority, together with addressing the needs of drug response gene minorities. A total of 72% also believed that postmarketing surveillance systems should be collecting DNA from patients experiencing moderate or severe adverse events.
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions